Actualités Celularity Inc - CELU | Actions NASDAQ

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

FLORHAM PARK, N.J. and ORLANDO, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused...

Celularity Releases CEO Letter to Shareholders

FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a longevity-focused...

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused...

Celularity Receives Nasdaq Notice Regarding Form 10-Q

FLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and...

Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation

FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused...

NEXGEL Appoints Ian Blackman as Chief Financial Officer

Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and...

NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

Transaction expected to approximately triple NEXGEL’s annual revenue to approximately $35 million and is...

Celularity Announces Closing of Transaction with NexGel

FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and...

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

FLORHAM PARK, N.J., April 17, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and...

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional...

Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in...

Celularity Strikes Up to $35M Licensing Deal for Biomaterials Portfolio

Celularity Inc. (NASDAQ:CELU) announced it has signed agreements for a strategic commercialization partnership involving its placental-derived...

NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to...

Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

Transaction expected to generate up to $35 million in upfront and milestone paymentsCelularity retains exclusive manufacturing rights, creating...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Celularity Inc (CELU)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Celularity Inc (CELU) Actualités

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Celularity Releases CEO Letter to Shareholders

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation

NEXGEL Appoints Ian Blackman as Chief Financial Officer

NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

Celularity Announces Closing of Transaction with NexGel

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

Celularity Strikes Up to $35M Licensing Deal for Biomaterials Portfolio

NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Celularity Inc (CELU)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Celularity Inc (CELU) Actualités

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Celularity Releases CEO Letter to Shareholders

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation

NEXGEL Appoints Ian Blackman as Chief Financial Officer

NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

Celularity Announces Closing of Transaction with NexGel

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

Celularity Strikes Up to $35M Licensing Deal for Biomaterials Portfolio

NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités